0000917520false00009175202026-07-292026-07-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 29, 2026
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact Name of Registrant as Specified in its Charter)
| | | | | | | | |
| Delaware | 0-26224 | 51-0317849 |
| (State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (IRS Employer Identification No.) |
1100 Campus Road
Princeton, NJ 08540
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 275-0500
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities Registered Pursuant to Section12(b) of the Act:
| | | | | | | | |
| Title of Each Class | Trading Symbol | Name of Exchange on Which Registered |
| Common Stock, Par Value $.01 Per Share | IART | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On July 29, 2026, Integra LifeSciences Holdings Corporation (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2026 (the “Press Release”). A copy of the Press Release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item. In the financial statements portion of the Press Release, the Company has included a reconciliation of GAAP revenues to organic revenues for the quarters ended June 30, 2026 and 2025, GAAP net income to adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) for the quarters ended June 30, 2026 and 2025, GAAP net income to adjusted net income for the quarters ended June 30, 2026 and 2025, GAAP gross profits to adjusted gross profits for the quarters ended June 30, 2026 and 2025, GAAP gross margin to adjusted gross margin for the quarters ended June 30, 2026 and 2025, GAAP earnings per diluted share to adjusted earnings per diluted share for the quarters ended June 30, 2026 and 2025, and GAAP total debt to net debt for the quarters ended June 30, 2026 and December 31, 2025.
In the Press Release, the Company provided forward-looking guidance regarding organic revenues and adjusted earnings per diluted share but did not provide reconciliations to the most directly comparable forward-looking GAAP financial measures because certain GAAP expense items and the impact of changes in foreign exchange rates are highly variable and management is unable to predict them with reasonable certainty and without unreasonable effort.
The information contained in Item 2.02 of this Current Report on Form 8-K (including the Press Release and selected historical financial information) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information contained in Item 2.02 of this Current Report on Form 8-K (including the Press Release and selected historical financial information) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted EBITDA, adjusted net income, adjusted gross profit, adjusted gross margin, adjusted earnings per diluted share, and net debt. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); (v) impairment charges; and (vi) those operating expenses also excluded from adjusted net income. The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) charges related to the transition of Boston-related manufacturing operations to the Company’s Braintree, Massachusetts facility (the “Braintree transition”); (v) intangible asset amortization expense; (vi) income tax impact from adjustments; and (vii) impairment charges. The measure of adjusted gross margin is calculated by dividing adjusted gross profit by total revenues. Adjusted gross profit consists of GAAP gross profit adjusted for: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) charges related to the recall and the transition of Boston-related manufacturing operations to the Company’s Braintree, Massachusetts facility; (iv) EU Medical Device Regulation-related charges; and (v) intangible asset amortization expense. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. The measure of net debt consists of GAAP total debt (excluding deferred financing costs) less short-term investments, cash and cash equivalents.
The Company believes that the presentation of organic revenues and the various adjusted EBITDA, adjusted net income, adjusted gross profit, adjusted gross margin, adjusted earnings per diluted share, and net debt measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. Management uses non-GAAP financial measures in the form of organic revenues, adjusted EBITDA, adjusted net income, adjusted gross profit, adjusted gross margin, adjusted earnings per diluted share, and net debt when evaluating operating performance because we believe that the inclusion or exclusion of the items described below, for which the amounts and/or timing may vary
significantly depending upon the Company's divestiture, acquisition, integration, and restructuring activities, for which the amounts are non-cash in nature, or for which the amounts are not expected to recur at the same magnitude, provides a supplemental measure of our operating results that facilitates comparability of our financial condition and operating performance from period to period, against our business model objectives, and against other companies in our industry. We have chosen to provide this information to investors so they can analyze our operating results in the same way that management does and use this information in their assessment of our core business and the valuation of our Company. In addition, since the Company has historically provided non-GAAP guidance to the investment community, we believe the continued inclusion of non-GAAP guidance provides consistency in the information made available to investors.
Organic revenues, adjusted EBITDA, adjusted net income, adjusted gross profit, adjusted gross margin, adjusted earnings per diluted share, and net debt are significant measures used by management for purposes of:
•supplementing the financial results and forecasts reported to the Company's board of directors;
•evaluating, managing and benchmarking the operating performance of the Company;
•establishing internal operating budgets;
•determining compensation under bonus or other incentive programs;
•enhancing comparability from period to period;
•comparing performance with internal forecasts and targeted business models; and
•evaluating and valuing potential acquisition candidates.
The measure of organic revenues that we report reflects the change in total revenues for the quarter ended June 30, 2026 adjusted for the effects of currency exchange rates, revenues from acquisitions, and revenues from divested products on current period revenues. We provide this measure because changes in foreign currency exchange rates can distort our reduction favorably or unfavorably, depending upon the strength of the U.S. dollar in relation to the various foreign currencies in which we generate revenues. We generate significant revenues outside the United States in multiple foreign currencies. We believe this measure provides useful information to determine the success of our international selling organizations in increasing sales of products in their local currencies without regard to fluctuations in currency exchanges rates, which we do not control. Additionally, significant divestitures and acquisitions can distort our current period revenues when compared to prior periods.
The measures of adjusted net income and adjusted gross profit reflect GAAP net income and GAAP gross profit, respectively, each adjusted for one or more of the following items, as applicable:
•Structural optimization charges. These charges include employee severance and other costs associated with exit or disposal of facilities, costs related to transferring manufacturing and/or distribution activities to different locations, and rationalization or enhancement of our organization, existing manufacturing, distribution, administrative, functional and commercial infrastructure. Some of these cost-saving and efficiency-driven activities are identified as opportunities in connection with acquisitions that provide the Company with additional capacity or economies of scale. Although recurring in nature, given management's ongoing review of the efficiency of our organization and structure, including manufacturing, distribution and administrative facilities and operations, management excludes these items when evaluating the operating performance of the Company because the frequency and amount of such charges vary significantly based on the timing and magnitude of the Company's rationalization activities and are, in some cases, dependent upon opportunities identified in acquisitions, which also vary in frequency and magnitude.
•Acquisition, divestiture and integration-related charges. Acquisition, divestiture and integration-related charges include (i) inventory fair value purchase accounting adjustments, (ii) changes in the fair value of contingent consideration after the acquisition date, (iii) costs related to acquisition integration, including systems, operations, retention and severance, (iv) legal, accounting, banking and other outside consultants expenses directly related to acquisitions or divestitures, and (v) gain or loss on sale of business and related costs to complete the divestiture of business. Although recurring, given the ongoing character of our acquisitions and divestitures, these charges are not factored into the evaluation of our performance by
management after completion because they are of a temporary nature, they are not related to our core operating performance and the frequency and amount of such charges vary significantly based on the timing and magnitude of our acquisition and divestiture transactions as well as the level of inventory on hand at the time of acquisition.
•EU Medical Device Regulation charges. These charges represent costs specific to complying with the medical device reporting regulations and other requirements of the European Union’s regulation for medical devices. Management excludes this item when evaluating the Company’s operating performance because these costs incurred are not reflective of its ongoing operations.
•Braintree transition charges. These charges represent costs and charges related to the transition of certain manufacturing operations from the Company’s Boston, Massachusetts facility to the Company’s Braintree, Massachusetts facility. Management excludes this item when evaluating the Company’s operating performance because of the infrequent and/or large scale nature of these activities.
•Intangible asset amortization expense. Management excludes this item when evaluating the Company's operating performance because it is a non-cash expense.
•Income tax impact from adjustments. This item represents adjustments to income tax expense for the amount of additional tax expense that the Company estimates that it would record if it used non-GAAP results instead of GAAP results in the calculation of its tax provision, based on the statutory rate applicable to jurisdictions in which the above non-GAAP adjustments relate.
•Impairment charges. These charges represent the impairment of goodwill due to the increased risk to the Company’s future results of operations from a number of factors, including recent tariff changes that have created broad economic uncertainty and the impact of quality, operational, and supply issues that have had a negative impact on the Company’s market capitalization. Management excludes this item when evaluating the Company's operating performance because it is a non-cash expense.
In the Press Release, the Company provided forward-looking guidance regarding organic revenues and adjusted earnings per diluted share but did not provide reconciliations to the most directly comparable forward-looking GAAP financial measures because certain GAAP expense items and the impact of changes in foreign exchange rates are highly variable and management is unable to predict them with reasonable certainty and without unreasonable effort. Specifically, the actual impact of changes in foreign exchange rates and the financial impact and timing of divestitures, acquisitions, integrations, structural optimization, efforts to comply with the EU Medical Device Regulation, and income tax impact from adjustments are uncertain, depend on various dynamic factors and are not reasonably ascertainable at this time. The unavailable information could have a material impact on GAAP results.
Organic revenues, adjusted EBITDA, adjusted net income, adjusted gross profit, adjusted gross margin, adjusted earnings per diluted share, and net debt are not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the revenues, costs or benefits associated with the operations of the Company's business as determined in accordance with GAAP. As a result, you should not consider these measures in isolation or as a substitute for analysis of the Company's results as reported under GAAP. The Company expects to continue to acquire businesses and product lines and to incur expenses of a nature similar to many of the non-GAAP adjustments described above, and exclusion of these items from its adjusted financial measures should not be construed as an inference that all of these revenue adjustments or costs are unusual, infrequent or non-recurring. Some of the limitations in relying on the adjusted financial measures are:
•The Company periodically acquires other companies or businesses, and we expect to continue to incur acquisition-related expenses and charges in the future. These costs can directly impact the amount of the Company's available funds or could include costs for aborted deals which may be significant and reduce GAAP net income.
•All of the adjustments to GAAP net income have been tax affected at the Company's actual tax rates. Depending on the nature of the adjustments and the tax treatment of the underlying items, the effective tax rate related to adjusted net income could differ significantly from the effective tax rate related to GAAP net income.
In the financial tables portion of the Press Release, the Company has included reconciliations of GAAP reported revenues to organic revenues, GAAP net income to adjusted EBITDA, GAAP net income to adjusted net income, GAAP gross profit to adjusted gross profit, GAAP gross margin to adjusted gross margin, and GAAP earnings per diluted share to adjusted earnings per diluted share each for the quarters ended June 30, 2026 and 2025. The Company has included a reconciliation of GAAP total debt to net debt for the quarters ended June 30, 2026 and December 31, 2025.
Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
99.1 Press Release with attachments, dated July 29, 2026, issued by Integra LifeSciences Holdings Corporation
104 Cover Page Interactive Data File (embedded within the inline XRBL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION |
| | |
| Date: July 29, 2026 | By: | /s/ Lea Knight |
| | Lea Knight |
| Title: | Executive Vice President and Chief Financial Officer |
| | |
| | |
| | |
| | |
News Release
Integra LifeSciences Reports Second Quarter 2026 Financial Results
PRINCETON, N.J., July 29, 2026 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.
Second Quarter 2026 Highlights
•Second quarter revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year.
•Second quarter GAAP earnings per diluted share of $0.06, compared to $(6.31) in the prior year.
•Adjusted earnings per diluted share of $0.56, compared to $0.45 in the prior year.
•The Company is updating its reported revenue guidance range to $1.654 billion to $1.695 billion to reflect the impact of a stronger U.S. dollar on foreign exchange rates.
•The Company is reaffirming its 2026 full-year organic revenue growth guidance of 0.8% to 3.3% and adjusted earnings per share guidance of $2.40 to $2.50.
•The Company initiated production at its Braintree manufacturing facility and remains on track for the planned fourth-quarter relaunch of SurgiMend®.
"Our second-quarter performance reflects meaningful progress on our most important priorities. We are improving supply reliability, advancing quality, and returning products to market with discipline. The Braintree facility is now producing and ramping to support the planned SurgiMend relaunch later this year," said Stuart Essig, Chairman and CEO of Integra LifeSciences.
"At the same time, we are seeing the benefits of a more aligned commercial organization while we continue to reduce our balance sheet leverage. Supported by our broad portfolio, attractive markets, and focused leadership team, we are strengthening our operating foundation and enhancing our ability to deliver sustainable long-term shareholder value."
Second Quarter 2026 Consolidated Performance
Total reported revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year.
The Company reported GAAP gross margin of 52.5%, compared to 50.4% in the second quarter of 2025. Adjusted gross margin was 61.3%, compared to 60.7% in the prior year.
Adjusted EBITDA for the second quarter of 2026 was $78.4 million, or 18.7% of revenue, compared to $71.2 million, or 17.1% of revenue, in the prior year.
The Company reported GAAP net income of $4.5 million, or $0.06 per diluted share, in the second quarter of 2026, compared to GAAP net loss of $(484.1) million, or $(6.31) per diluted share, in the prior year.
Adjusted net income for the second quarter of 2026 was $43.7 million, or $0.56 per diluted share, compared to $34.4 million, or $0.45 per diluted share, in the prior year.
Second Quarter 2026 Segment Performance
Specialty Surgery (~70% of Revenues)
Total revenues were $309.3 million, representing reported growth of 1.7% and an organic growth of 1.6% compared to the second quarter of 2025.
•Sales in Neuro increased 1.9% on an organic basis primarily driven by growth in Certas® Plus, Bactiseal® and CUSA®.
•Sales in Instruments grew 3.2% on an organic basis.
•ENT sales declined (1.9%) as MicroFrance® ENT instrument growth was offset by declines in other products.
Tissue Reconstruction (~30% of Revenues)
Total revenues were $109.5 million, representing reported and organic declines of (1.9)% and (2.0)% respectively compared to the second quarter of 2025. Key drivers for the quarter include:
•Mid-single digit decline in wound reconstruction, driven by strong growth in DuraSorb® and the relaunch of PriMatrix®, offset by declines in MicroMatrix® and Integra Skin. Integra Skin faced a prior year comparison that included the clearance of back orders in the second quarter of 2025.
•Sales in private label grew 4.7%.
Balance Sheet, Cash Flow and Capital Allocation
The Company generated cash flow from operations of $22.8 million in the quarter. Net debt at the end of the quarter was $1.6 billion, and the consolidated total leverage ratio was 4.1x.
As of the end of the quarter, the Company had total liquidity of approximately $496 million, including $274.1 million in cash plus short-term investments and the remainder available under its revolving credit facility.
2026 Revenue and Adjusted Earnings Per Share Guidance
For the third quarter of 2026, the Company expects reported revenues in the range of $410 million to $425 million, representing reported growth of 2.0% to 5.7% and organic growth of 1.9% to 5.7%. The Company expects adjusted EPS in the range of $0.53 to $0.61 per share.
The Company is updating its reported revenue outlook from a range of $1.662 billion to $1.702 billion to a range of $1.654 billion to $1.695 billion to reflect the impact of a stronger U.S. dollar on foreign exchange rates. For the full year 2026, the Company is reaffirming its organic revenue growth guidance of 0.8% to 3.3% and adjusted earnings per share guidance of $2.40 to $2.50. The adjusted EPS outlook reflects updated tariff assumptions, a higher interest rate environment, and potential debt refinancing actions.
The Company's organic sales growth guidance for the third quarter and full year excludes the impact of acquisitions, divestitures, and foreign currency.
Conference Call and Presentation Available Online
Integra has scheduled a conference call for 8:30 a.m. ET on Wednesday, July 29, 2026, to discuss second quarter 2026 financial results and forward-looking financial guidance. The conference call will be hosted by Integra's senior management team and will be open to all listeners. Additional forward-looking information may be discussed in a question-and-answer session following the call. Integra's management team will reference a presentation during the conference call, which can be found on the Investor section of the website at investor.integralife.com.
A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, it is recommended to join 10 minutes prior to the event’s start. A webcast replay of the conference call will be available on the Investors section of the company's website following the call.
About Integra
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” "forecast," "guidance," “plan,” “anticipate,” "target," or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning: future business, operational and financial performance and the Company’s expectations and plans with respect to market opportunity, business and operational performance, strategic initiatives, capabilities, resources, manufacturing capabilities, product development, product availability and regulatory approvals, including expectations regarding the Company's Braintree facility and the the relaunch of SurgiMend in the fourth quarter of 2026. It is important to note that the Company’s goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited, to the following: increased geopolitical instability and other macroeconomic factors, including trade barriers and related restrictions (including tariffs and related countermeasures), armed conflict and acts of terrorism, geopolitical tension and instability, supply chain disruptions, and interest rate and foreign currency rate fluctuations, on the Company’s suppliers, vendors and customers and on the Company’s business and financial condition, results of operations and cash flows; the Company's ability to execute its financial, strategic and operating plans effectively; the Company's ability to remediate quality systems violations; difficulties in implementing the Company’s compliance master plan; difficulties or delays in obtaining and maintaining required regulatory approvals, including the costs thereof; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products; the failure of the company’s suppliers, vendors, and other third parties to meet contractual, regulatory and other obligations; the anticipated development of markets the Company sells its products into and the success of the Company’s products in these markets; the Company’s ability to predict accurately the demand for its products and products under development; increasing industry competition; the coverage and reimbursement decisions of third-party payors; trends toward health care cost containment; difficulties in controlling expenses, including costs to procure and manufacture the Company’s products; the ability of the Company to successfully manage leadership and organizational changes and the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the geographic distribution of where the Company generates its taxable income; changes to applicable laws, regulations and enforcement guidance, including tax laws and global health care reforms; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; breaches, failures or other disruptions of our or our vendors’ or customers’
information technology systems or products; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2025 and information contained in subsequent filings with the Securities and Exchange Commission.
These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise, except as otherwise required by law.
Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted net income, adjusted gross margin, adjusted earnings per diluted share, and net debt. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); (v) impairment charges; and (vi) those operating expenses also excluded from adjusted net income. The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) EU Medical Device Regulation-related charges; (iv) charges related to the transition of Boston-related manufacturing operations to the Company’s Braintree, Massachusetts facility (the "Braintree transition"); (v) intangible asset amortization expense; (vi) income tax impact from adjustments; and (vii) impairment charges. The measure of adjusted gross margin is calculated by dividing adjusted gross profit by total revenues. Adjusted gross profit consists of GAAP gross profit adjusted for: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) charges related to Braintree transition; (iv) EU Medical Device Regulation-related charges; and (v) intangible asset amortization expense. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. The measure of net debt consists of GAAP total debt (excluding deferred financing costs) less short-term investments, cash and cash equivalents.
The Company has included reconciliations of GAAP revenues to organic revenues, GAAP net income to adjusted EBITDA, and adjusted net income, GAAP gross margin to adjusted gross margin, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarters ended June 30, 2026 and 2025. The Company has included a reconciliation of GAAP total debt to net debt for the quarters ended June 30, 2026 and December 31, 2025.
The Company is providing forward-looking guidance regarding organic revenue and adjusted earnings per diluted share but is not providing reconciliations to the most directly comparable forward-looking GAAP financial measures because certain GAAP expense items and the impact of changes in foreign exchange rates are highly variable and management is unable to predict them with reasonable certainty and without unreasonable effort. Specifically, the actual impact of changes in foreign exchange rates and the financial impact and timing of divestitures, acquisitions, integrations, structural optimization, efforts to comply with the EU Medical Device Regulation, and income tax impact from adjustments are uncertain, depend on various dynamic factors and are not reasonably ascertainable at this time. The unavailable information could have a material impact on GAAP results.
The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com.
Investor Relations Contact:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(In thousands, except per share amounts)
| | | | | | | | | | | |
| Three Months Ended June 30, |
| 2026 | | 2025 |
| Total revenue, net | $ | 418,761 | | | $ | 415,605 | |
| | | |
| Costs and expenses: | | | |
| Cost of goods sold | 199,017 | | | 206,273 | |
| Research and development | 24,253 | | | 26,997 | |
| Selling, general and administrative | 172,436 | | | 179,890 | |
| Intangible asset amortization | 3,770 | | | 3,754 | |
| Goodwill impairment charge | — | | | 511,365 | |
| Total costs and expenses | 399,476 | | | 928,279 | |
| Operating income (loss) | 19,285 | | | (512,674) | |
| Interest income | 4,267 | | | 4,710 | |
| Interest expense | (22,994) | | | (21,042) | |
| | | |
| Other income (expense), net | 4,186 | | | (1,946) | |
| Income (loss) before income taxes | 4,744 | | | (530,952) | |
| Provision (benefit) for income taxes | 262 | | | (46,879) | |
| Net income (loss) | $ | 4,482 | | | $ | (484,073) | |
| | | |
| Net income (loss) per share | | | |
| Diluted | $0.06 | | $(6.31) |
| | | |
| Weighted average common shares outstanding | 78,168 | | | 76,695 | |
| | | |
The following table presents revenues disaggregated by the major sources for the three months ended June 30, 2026 and 2025 (amounts in thousands):
| | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | | | |
| 2026 | 2025 | Change | | | | |
| Neurosurgery | $ | 213,264 | | $ | 208,992 | | 2.0% | | | | |
| Instruments | 54,806 | | 53,080 | | 3.3% | | | | |
| ENT | 41,199 | | 41,886 | | (1.6)% | | | | |
| Total Specialty Surgical | 309,269 | | 303,958 | | 1.7% | | | | |
| | | | | | | |
| Wound Reconstruction Solutions | 81,305 | | 84,747 | | (4.1)% | | | | |
| Private Label | 28,187 | | 26,900 | | 4.8% | | | | |
| Total Tissue Reconstruction | 109,492 | | 111,647 | | (1.9)% | | | | |
| Total Reported Revenues | $ | 418,761 | | $ | 415,605 | | 0.8% | | | | |
| | | | | | | |
| Impact of changes in currency exchange rates | (440) | | — | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Total organic revenues(1) | $ | 418,316 | | $ | 415,605 | | 0.7% | | | | |
(1) Organic revenues have been adjusted to exclude foreign currency (current period), acquisitions and to account for divested and discontinued products.
Items included in GAAP net income and location where each item is recorded are as follows:
(In thousands)
Three Months Ended June 30, 2026
| | | | | | | | | | | | | | | | | | | | | | | |
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort (d) | OI&E(e) | Tax(f) |
| Acquisition, divestiture and integration-related charges | 2,383 | 35 | 1,503 | 599 | — | 247 | — |
| Structural Optimization charges | 7,513 | 3,366 | 4,094 | 53 | — | — | — |
| EU Medical Device Regulation charges | 2,439 | 218 | 1,017 | 1,205 | — | — | — |
| Braintree Transition | 9,918 | 10,309 | (398) | 7 | — | — | — |
| Intangible asset amortization expense | 26,969 | 23,198 | — | — | 3,770 | — | — |
| Estimated income tax impact from above adjustments and other items | (9,992) | — | — | — | — | — | (9,992) |
| Depreciation expense | 10,154 | — | — | — | — | — | — |
a)COGS - Cost of goods sold
b)SG&A - Selling, general and administrative
c)R&D - Research & development
d)Amort. - Intangible asset amortization
e)OI&E - Other income & expense
f)Tax - Income tax expense (benefit)
Items included in GAAP net income and location where each item is recorded are as follows:
(In thousands)
Three Months Ended June 30, 2025
| | | | | | | | | | | | | | | | | | | | | | | |
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort (d) | OI&E(e) | Tax(f) |
| Acquisition, divestiture and integration-related charges | 4,963 | | — | | 4,258 | | 270 | | — | | 435 | | — | |
| Structural Optimization charges | 5,944 | | 5,187 | | 1,073 | | (316) | | — | | — | | — | |
| EU Medical Device Regulation charges | 10,681 | | 1,142 | | 4,200 | | 5,338 | | — | | — | | — | |
| Braintree Transition | 13,630 | | 13,532 | | 98 | | — | | — | | — | | — | |
| Intangible asset amortization expense | 26,795 | | 23,041 | | — | | — | | 3,754 | | — | | — | |
| Estimated income tax impact from above adjustments and other items | (54,940) | | — | | — | | — | | — | | — | | (54,940) | |
| Depreciation expense | 10,955 | | — | | — | | — | | — | | — | | — | |
a)COGS - Cost of goods sold
b)SG&A - Selling, general and administrative
c)R&D - Research & development
d)Amort. - Intangible asset amortization
e)OI&E - Other income & expense
f)Tax - Income tax expense (benefit)
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO ADJUSTED EBITDA
(UNAUDITED)
(In thousands)
| | | | | | | | | | | |
| Three Months Ended June 30, |
| 2026 | | 2025 |
| | | |
| GAAP net income (loss) | $ | 4,482 | | | $ | (484,073) | |
| Non-GAAP adjustments: | | | |
| Goodwill impairment charges | — | | | 511,365 | |
| Depreciation and intangible asset amortization expense | 37,123 | | | 37,750 | |
| Other (income) expense, net | (4,186) | | | 1,511 | |
| Interest expense, net | 18,480 | | | 16,332 | |
| Income tax expense | 262 | | | (46,879) | |
| Structural optimization charges | 7,513 | | | 5,944 | |
| EU Medical Device Regulation charges | 2,439 | | | 10,681 | |
| Braintree Transition | 9,918 | | | 13,630 | |
| Acquisition, divestiture and integration-related charges | 2,383 | | | 4,963 | |
| Total of non-GAAP adjustments | 73,932 | | | 555,297 | |
| Adjusted EBITDA | $ | 78,414 | | | $ | 71,224 | |
| | | |
| | | |
| | | |
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE
(UNAUDITED)
(In thousands, except per share amounts)
| | | | | | | | | | | |
| Three Months Ended June 30, |
| 2026 | | 2025 |
| | | |
| GAAP net income (loss) | $ | 4,482 | | | $ | (484,073) | |
| Non-GAAP adjustments: | | | |
| Structural optimization charges | 7,513 | | | 5,944 | |
| Acquisition, divestiture and integration-related charges | 2,383 | | | 4,963 | |
| EU Medical Device Regulation charges | 2,439 | | | 10,681 | |
| Braintree Transition | 9,918 | | | 13,630 | |
| Goodwill impairment charges | — | | | 511,365 | |
| Intangible asset amortization expense | 26,969 | | | 26,795 | |
| Estimated income tax impact from adjustments and other items | (9,992) | | | (54,940) | |
| Total of non-GAAP adjustments | 39,230 | | | 518,438 | |
| Adjusted net income | $ | 43,712 | | | $ | 34,365 | |
| | | |
| Adjusted diluted net income per share | $ | 0.56 | | | $ | 0.45 | |
| Weighted average common shares outstanding for diluted net income per share | 78,168 | | | 76,769 | |
CONDENSED BALANCE SHEET DATA
(UNAUDITED)
(In thousands)
| | | | | | | | | | | |
| June 30,
2026 | | December 31,
2025 |
| | | |
| Short term investments | $ | 59,669 | | | $ | 28,693 | |
| Cash and cash equivalents | 214,415 | | | 235,048 | |
| Trade accounts receivable, net | 267,188 | | | 278,849 | |
| Inventories, net | 492,005 | | | 492,735 | |
| | | |
| Current and long-term borrowing under senior credit facility | 1,779,699 | | | 1,768,306 | |
| Borrowings under securitization facility | 92,600 | | | 87,800 | |
| Convertible securities | — | | | — | |
| | | |
| | | |
| Stockholders' equity | $ | 1,043,377 | | | $ | 1,043,463 | |
| | | |
| | | |
CONDENSED STATEMENT OF CASH FLOWS
(UNAUDITED)
(In thousands)
| | | | | | | | | | | |
| Six Months Ended June 30, |
| 2026 | | 2025 |
| | | |
| Net cash (used) provided by operating activities | $ | 32,605 | | | $ | (2,338) | |
| Net cash used in investing activities | (58,131) | | | (57,568) | |
| Net cash provided by financing activities | 7,479 | | | 14,238 | |
| Effect of exchange rate changes on cash and cash equivalents | (2,586) | | | 17,207 | |
| | | |
| Net decrease in cash and cash equivalents | $ | (20,633) | | | $ | (28,461) | |
| | | |
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO
MEASURES OF FREE CASH FLOW AND ADJUSTED FREE CASH FLOW CONVERSION
(UNAUDITED)
(In thousands)
| | | | | | | | |
| Three Months Ended June 30, |
| 2026 | 2025 |
| Net cash provided by operating activities | $ | 22,802 | | $ | 8,919 | |
| | |
| Purchases of property and equipment | (12,307) | | (20,146) | |
| Free cash flow | $ | 10,495 | | $ | (11,227) | |
| | |
Adjusted net income(1) | $ | 43,712 | | $ | 34,365 | |
| Adjusted free cash flow conversion | 24.0 | % | (32.7) | % |
| | |
| | |
| | |
| Twelve Months Ended June 30, |
| 2026 | 2025 |
| Net cash provided by operating activities | $ | 85,327 | | $ | 70,888 | |
| | |
| Purchases of property and equipment | (59,525) | | (108,311) | |
| Free cash flow | $ | 25,802 | | $ | (37,423) | |
| | |
Adjusted net income(1) | $ | 190,633 | | $ | 171,011 | |
| Adjusted free cash flow conversion | 13.5 | % | (21.9) | % |
| | |
(1) Adjusted net income for quarters ended June 30, 2026 and 2025 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com under Events & Presentations.
The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income. The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.
RECONCILIATION OF NON-GAAP ADJUSTMENTS - NET DEBT CALCULATION
(UNAUDITED)
| | | | | | | | |
| (In thousands) | |
| June 30,
2026 | December 31,
2025 |
| Short-term borrowings under senior credit facility | $ | 43,594 | | $ | 38,750 | |
| Long-term borrowings under senior credit facility | 1,736,105 | | 1,729,556 | |
| Borrowings under securitization facility | 92,600 | | 87,800 | |
| Convertible securities | — | | — | |
| Deferred financing costs netted in the above | 2,489 | | 3,257 | |
| Short term investments | (59,669) | | (28,693) | |
| Cash & Cash Equivalents | (214,415) | | (235,048) | |
| Net Debt | $ | 1,600,704 | | $ | 1,595,622 | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP GROSS PROFIT TO MEASURES OF ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN
(UNAUDITED)
(In thousands, except percentages)
| | | | | | | | | | | |
| Three Months Ended June 30, |
| 2026 | | 2025 |
| | | |
| Total revenues, net | $ | 418,761 | | | $ | 415,605 | |
| Cost of goods sold | 199,017 | | | 206,273 | |
| Reported Gross Profit | 219,744 | | | 209,332 | |
| Structural optimization charges | 3,366 | | | 5,187 | |
| Acquisition, divestiture and integration-related charges | 35 | | | — | |
| Braintree Transition | 10,309 | | | 13,532 | |
| EU Medical Device Regulation | 218 | | | 1,142 | |
| Intangible asset amortization expense | 23,199 | | | 23,041 | |
| Adjusted Gross Profit | $ | 256,871 | | | $ | 252,234 | |
| Total Revenues | $ | 418,761 | | | $ | 415,605 | |
| Adjusted Gross Margin | 61.3 | % | | 60.7 | % |
| | | |
| | | |
| | | |
| | | |
